Home・Aandelen Lijst・Viking Therapeutics Inc

Viking Therapeutics Inc

Gesloten

SectorGezondheidszorg

32.81 0.71

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

32.47

Max

33.51

Belangrijke statistieken
By Trading Economics
Inkomsten	30M -128M
EPS	-1.1
Werknemers	65
EBITDA	30M -128M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+182.37% upside

Dividenden
By Acuity
Volgende Winsten	21 okt 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-245M 3.8B
Vorige openingsprijs	32.1
Vorige sluitingsprijs	32.81

Nieuwssentiment

By Acuity

50%

175 / 340 Rangschikking in Healthcare

Viking Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 aug 2026, 23:02 UTC

Social Media

Viking Therapeutics Inc shares are lower in after-market hours amid routine trading. The stock remains below its 20-day moving average.

3 aug 2026, 23:06 UTC

Viking Therapeutics shares are higher in after-market trading, reflecting positive sentiment from stronger-than-expected manufacturing PMI data indicating sector growth.

31 jul 2026, 23:51 UTC

Viking Therapeutics Inc is higher in after-market trading, recovering from earlier session lows after four consecutive declines. The stock remains below its 20-day moving average.

30 jul 2026, 23:56 UTC

News

Viking Therapeutics Inc. shows a modest gain in after-market hours amid a wave of biopharmaceutical mergers, including Vertex's $10 billion acquisition of Crinetics.

29 jul 2026, 23:21 UTC

Social Media

News

Viking Therapeutics reported a Q2 loss of $1.10 per share, better than expected. The company highlighted progress in its obesity treatment pipeline.

28 jul 2026, 23:11 UTC

News

Viking Therapeutics shares are lower in after-market hours amid ongoing challenges and a significant decline over the past two years. Analysts maintain a bullish outlook.

27 jul 2026, 23:56 UTC

Viking Therapeutics Inc shares are lower in after-market hours, reflecting a lack of specific news and remaining below the 20-day moving average.

25 jul 2026, 00:01 UTC

Viking Therapeutics Inc shares are lower in after-market trading, continuing a trend of four consecutive sessions finishing down. No specific news was identified.

24 jul 2026, 21:01 UTC

Viking Therapeutics Inc. is higher in after-market trading, reversing recent losses despite no specific news driving the price movement.

23 jul 2026, 23:46 UTC

Event

Viking Therapeutics shares are higher in after-market trading ahead of Q2 earnings, with estimated EPS of -$1.21, up from -$0.58.

22 jul 2026, 23:36 UTC

Viking Therapeutics Inc. shares showed little change during after-market hours, trading within a narrow range and settling near unchanged levels.

Peer Vergelijking

Prijswijziging

Viking Therapeutics Inc Prognose

Koersdoel

By TipRanks

182.37% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 92.08 USD 182.37%

Hoogste 114 USD

Laagste 70 USD

Gebaseerd op 14 Wall Street-analisten die 12-maands prijsdoelen bieden voor Viking Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

14 ratings

Buy

Hold

Sell

Gebaseerd op 14 analisten die aandelenratings hebben gegeven aan Viking Therapeutics Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

175 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.